Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
In 1986, Kärre and colleagues reported that natural killer (NK) cells rejected an MHC class I-deficient tumor cell line (RMA-S) but they did not reject the same cell line if it expressed MHC class I (RMA). Based on this observation, they proposed the concept that NK cells provide immune surveillance for “missing self,” e.g., they eliminate cells that have lost class I MHC antigens. This seminal observation predicted the existence of inhibitory NK cell receptors for MHC class I. Here, we present evidence that NK cells are able to reject tumors expressing MHC class I if the tumor expresses a ligand for NKG2D. Mock-transfected RMA cells resulted in tumor formation. In contrast, when RMA cells were transfected with the retinoic acid early inducible gene-1 γ or δ (RAE-1), ligands for the activating receptor NKG2D, the tumors were rejected. The tumor rejection was mediated by NK cells, and not by CD1-restricted NK1.1 + T cells. No T cell-mediated immunological memory against the parental tumor was generated in the animals that had rejected the RAE-1 transfected tumors, which succumbed to rechallenge with the parental RMA tumor. Therefore, NK cells are able to reject a tumor expressing RAE-1 molecules, despite expression of self MHC class I on the tumor, demonstrating the potential for NK cells to participate in immunity against class I-bearing malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“NKG2D has been implicated in immune surveillance of tumors using transgenic models of spontaneous cancer as well as subcutaneous tumor transfer models (Cerwenka et al., 2001; Diefenbach et al., 2001; Guerra et al., 2008).”
From p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells (2013) · cites this paper as Cerwenka et al., 2001
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 2,999
Self-citationBiology of Natural Killer Cells
Trinchieri, G. (1989) · Advances in Immunology · doi:10.1016/s0065-2776(08)60664-1 · Cited by 2,902
Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy
Kärre, K., Ljunggren, H. G., Piontek, G., & Kiessling, R. (1986) · Nature · doi:10.1038/319675a0 · Cited by 2,161
NATURAL KILLER CELLS IN ANTIVIRAL DEFENSE: Function and Regulation by Innate Cytokines
Biron, C. A., Nguyen, K. B., Pien, G. C., Cousens, L. P., & Salazar-Mather, T. P. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.189 · Cited by 2,113
Lanier, L. L. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.359 · Cited by 1,648
Self-citationCosman, D., Müllberg, J., Sutherland, C. L., Chin, W., Armitage, R., Fanslow, W., Kubin, M., & Chalupny, N. J. (2001) · Immunity · doi:10.1016/s1074-7613(01)00095-4 · Cited by 1,232
An Activating Immunoreceptor Complex Formed by NKG2D and DAP10
Wu, J., Song, Y., Bakker, A. B. H., Bauer, S., Spies, T., Lanier, L. L., & Phillips, J. H. (1999) · Science · doi:10.1126/science.285.5428.730 · Cited by 1,039
Self-citationBroad tumor-associated expression and recognition by tumor-derived γδ T cells of MICA and MICB
Groh, V., Rhinehart, R., Secrist, H., Bauer, S., Grabstein, K. H., & Spies, T. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.6879 · Cited by 1,028
Groh, V, Bahram, S., Bauer, S., Herman, A., Beauchamp, M., & Spies, T. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.22.12445 · Cited by 1,017
Costimulation of CD8αβ T cells by NKG2D via engagement by MIC induced on virus-infected cells
Groh, V., Rhinehart, R., Randolph-Habecker, J., Topp, M. S., Riddell, S. R., & Spies, T. (2001) · Nature Immunology · doi:10.1038/85321 · Cited by 951
Research works printed but not linked: 2
- 10.1146/annurev.iy.10.040192.001201 · doi:10.1146/annurev.iy.10.040192.001201 · Paper page
- S Bahram Adv Immunol 76, 1–60 (2000).
Cited by
Functions of natural killer cells
Vivier, E., Tomasello, E., Baratin, M., Walzer, T., & Ugolini, S. (2008) · Nature Immunology · doi:10.1038/ni1582 · Cited by 3,943
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
Lanier, L. L. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115526 · Cited by 2,769
Self-citationTumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
Groh, V., Wu, J., Yee, C., & Spies, T. (2002) · Nature · doi:10.1038/nature01112 · Cited by 1,592
Roles of the NKG2D immunoreceptor and its ligands
Raulet, D. H. (2003) · Nature Reviews Immunology · doi:10.1038/nri1199 · Cited by 1,348
NK cells and cancer: you can teach innate cells new tricks
Morvan, M. G., & Lanier, L. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.5 · Cited by 1,162
Self-citationNatural killer cells, viruses and cancer
Cerwenka, A., & Lanier, L. L. (2001) · Nature Reviews Immunology · doi:10.1038/35095564 · Cited by 875
Self-citationSmyth, M. J., Dunn, G. P., & Schreiber, R. D. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90001-7 · Cited by 870
Bryceson, Y. T., March, M. E., Ljunggren, H.-G., & Long, E. O. (2006) · Blood · doi:10.1182/blood-2005-04-1351 · Cited by 863
NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy
Guerra, N., Tan, Y. X., Joncker, N. T., Choy, A., Gallardo, F., Xiong, N., Knoblaugh, S., Cado, D., Greenberg, N. R., & Raulet, D. H. (2008) · Immunity · doi:10.1016/j.immuni.2008.02.016 · Cited by 850
Does the Immune System See Tumors as Foreign or Self?
Pardoll, D. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141135 · Cited by 753
New aspects of natural-killer-cell surveillance and therapy of cancer
Smyth, M. J., Hayakawa, Y., Takeda, K., & Yagita, H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc928 · Cited by 752
Activation of NK cell cytotoxicity
Smyth, M. J., Cretney, E., Kelly, J. M., Westwood, J. A., Street, S. E. A., Yagita, H., Takeda, K., Dommelen, S. L. H. V., Degli-Esposti, M. A., & Hayakawa, Y. (2005) · Molecular Immunology · doi:10.1016/j.molimm.2004.07.034 · Cited by 714
Neutrophil-derived cytokines: facts beyond expression
Tecchio, C., Micheletti, A., & Cassatella, M. A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00508 · Cited by 699
NK cells and cancer immunosurveillance
Waldhauer, I., & Steinle, A. (2008) · Oncogene · doi:10.1038/onc.2008.267 · Cited by 682
“In vivo experiments assessing a functional role of NKG2DL for tumour surveillance demonstrated that ectopic expression of Rae1b and H60 conferred a strong immunostimulatory capacity to otherwise tumour-forming malignant cell lines (Cerwenka et al., 2001; Diefenbach et al., 2001).”
BackgroundThe Role of the NKG2D Immunoreceptor in Immune Cell Activation and Natural Killing
Jamieson, A. M., Diefenbach, A., McMahon, C. W., Xiong, N., Carlyle, J. R., & Raulet, D. H. (2002) · Immunity · doi:10.1016/s1074-7613(02)00333-3 · Cited by 647
Cutting Edge: Down-Regulation of MICA on Human Tumors by Proteolytic Shedding
Salih, H. R., Rammensee, H.-G., & Steinle, A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.8.4098 · Cited by 643
NKG2D Receptor and Its Ligands in Host Defense
Lanier, L. L. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0098 · Cited by 599
Self-citationFernandez, N. C., Treiner, E., Vance, R. E., Jamieson, A. M., Lemieux, S., & Raulet, D. H. (2005) · Blood · doi:10.1182/blood-2004-08-3156 · Cited by 588
Roles of natural killer cells in immunity to cancer, and applications to immunotherapy
Wolf, N. K., Kissiov, D. U., & Raulet, D. H. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00732-1 · Cited by 577
NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
Wang, W. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00368 · Cited by 567
Activating and inhibitory receptors of natural killer cells
Pegram, H. J., Andrews, D. M., Smyth, M. J., Darcy, P. K., & Kershaw, M. H. (2011) · Immunology & Cell Biology · doi:10.1038/icb.2010.78 · Cited by 555
Lee, J.-C., Lee, K.-M., Kim, D.-W., & Heo, D. S. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.12.7335 · Cited by 549
Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia
Salih, H. R., Antropius, H., Gieseke, F., Lutz, S. Z., Kanz, L., Rammensee, H.-G., & Steinle, A. (2003) · Blood · doi:10.1182/blood-2003-01-0019 · Cited by 541
Regulation of immune cell function and differentiation by the NKG2D receptor
Zafirova, B., Wensveen, F. M., Gulin, M., & Polić, B. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0797-0 · Cited by 538
Human natural killer cell development and biology
Farag, S. S., & Caligiuri, M. A. (2006) · Blood Reviews · doi:10.1016/j.blre.2005.10.001 · Cited by 506
The NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies
Bald, T., Krummel, M. F., Smyth, M. J., & Barry, K. C. (2020) · Nature Immunology · doi:10.1038/s41590-020-0728-z · Cited by 506
Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect
Farag, S. S., Fehniger, T. A., Ruggeri, L., Velardi, A., & Caligiuri, M. A. (2002) · Blood · doi:10.1182/blood-2002-02-0350 · Cited by 491
Effect of NKG2D ligand expression on host immune responses
Champsaur, M., & Lanier, L. L. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2010.00893.x · Cited by 488
Self-citationThe E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells
Paolino, M., Choidas, A., Wallner, S., Pranjic, B., Uribesalgo, I., Loeser, S., Jamieson, A. M., Langdon, W. Y., Ikeda, F., Fededa, J. P., et al. (2014) · Nature · doi:10.1038/nature12998 · Cited by 456
Oppenheim, D. E., Roberts, S. J., Clarke, S. L., Filler, R., Lewis, J. M., Tigelaar, R. E., Girardi, M., & Hayday, A. C. (2005) · Nature Immunology · doi:10.1038/ni1239 · Cited by 454
Hsu, K. C., Chida, S., Geraghty, D. E., & Dupont, B. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.19004.x · Cited by 443
Natural Killer Cell Education and Tolerance
Orr, M. T., & Lanier, L. L. (2010) · Cell · doi:10.1016/j.cell.2010.08.031 · Cited by 441
Self-citationNatural Killer Cells and Cancer
(2003) · Advances in Cancer Research · doi:10.1016/s0065-230x(03)90004-2 · Cited by 438
Self-citationNKG2D recruits two distinct adapters to trigger NK cell activation and costimulation
Gilfillan, S., Ho, E. L., Cella, M., Yokoyama, W. M., & Colonna, M. (2002) · Nature Immunology · doi:10.1038/ni857 · Cited by 437
CD4+CD25+ T Regulatory Cells Suppress NK Cell-Mediated Immunotherapy of Cancer
Smyth, M. J., Teng, M. W. L., Swann, J., Kyparissoudis, K., Godfrey, D. I., & Hayakawa, Y. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.3.1582 · Cited by 420
Iannello, A., Thompson, T. W., Ardolino, M., Lowe, S. W., & Raulet, D. H. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130783 · Cited by 414
Interplay of natural killer cells and their receptors with the adaptive immune response
Raulet, D. H. (2004) · Nature Immunology · doi:10.1038/ni1114 · Cited by 413
NKG2D ligands in tumor immunity
Nausch, N., & Cerwenka, A. (2008) · Oncogene · doi:10.1038/onc.2008.272 · Cited by 408
Self-citationOncogenic stress sensed by the immune system: role of natural killer cell receptors
Raulet, D. H., & Guerra, N. (2009) · Nature Reviews Immunology · doi:10.1038/nri2604 · Cited by 404
Recognition of Tumors by the Innate Immune System and Natural Killer Cells
Marcus, A., Gowen, B. G., Thompson, T. W., Iannello, A., Ardolino, M., Deng, W., Wang, L., Shifrin, N., & Raulet, D. H. (2014) · Advances in Immunology · doi:10.1016/b978-0-12-800267-4.00003-1 · Cited by 394
Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells
Verneris, M. R., Karami, M., Baker, J., Jayaswal, A., & Negrin, R. S. (2004) · Blood · doi:10.1182/blood-2003-06-2125 · Cited by 383
Natural Killer Cell Accumulation in Tumors Is Dependent on IFN-γ and CXCR3 Ligands
Wendel, M., Galani, I. E., Suri-Payer, E., & Cerwenka, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1440 · Cited by 378
Self-citationDisulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands
Kaiser, B. K., Yim, D., Chow, I.-T., Gonzalez, S., Dai, Z., Mann, H. H., Strong, R. K., Groh, V., & Spies, T. (2007) · Nature · doi:10.1038/nature05768 · Cited by 377
Tumor-Associated MICA Is Shed by ADAM Proteases
Waldhauer, I., Goehlsdorf, D., Gieseke, F., Weinschenk, T., Wittenbrink, M., Ludwig, A., Stevanovic, S., Rammensee, H.-G., & Steinle, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6768 · Cited by 375
Promiscuity and the single receptor: NKG2D
Eagle, R. A., & Trowsdale, J. (2007) · Nature Reviews Immunology · doi:10.1038/nri2144 · Cited by 374
“Cancer as a drive for NKG2D-ligand diversity? NKG2D is known to participate in antitumour immune responses, immune surveillance and suppression of experimentally induced tumour”
BackgroundPogge von Strandmann, E., Simhadri, V. R., von Tresckow, B., Sasse, S., Reiners, K. S., Hansen, H. P., Rothe, A., Böll, B., Simhadri, V. L., Borchmann, P., et al. (2007) · Immunity · doi:10.1016/j.immuni.2007.10.010 · Cited by 374
Hedlund, M., Nagaeva, O., Kargl, D., Baranov, V., & Mincheva-Nilsson, L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016899 · Cited by 360
Armeanu, S., Bitzer, M., Lauer, U. M., Venturelli, S., Pathil, A., Krusch, M., Kaiser, S., Jobst, J., Smirnow, I., Wagner, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4252 · Cited by 358
Induction of tumor-specific T cell memory by NK cell–mediated tumor rejection
Kelly, J. M., Darcy, P. K., Markby, J. L., Godfrey, D. I., Takeda, K., Yagita, H., & Smyth, M. J. (2002) · Nature Immunology · doi:10.1038/ni746 · Cited by 356
Carbone, E. (2005) · Blood · doi:10.1182/blood-2004-04-1422 · Cited by 333
Wu, J. D., Higgins, L. M., Steinle, A., Cosman, D., Haugk, K., & Plymate, S. R. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422206 · Cited by 330
Evasion from NK Cell Immunity by MHC Class I Chain-Related Molecules Expressing Colon Adenocarcinoma
Doubrovina, E. S., Doubrovin, M. M., Vider, E., Sisson, R. B., O’Reilly, R. J., Dupont, B., & Vyas, Y. M. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.12.6891 · Cited by 324
Immunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy
Riera-Domingo, C., Audigé, A., Granja, S., Cheng, W.-C., Ho, P.-C., Baltazar, F., Stockmann, C., & Mazzone, M. (2020) · Physiological Reviews · doi:10.1152/physrev.00018.2019 · Cited by 310
Hazeldine, J., & Lord, J. M. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2013.04.003 · Cited by 308
Friese, M. A., Wischhusen, J., Wick, W., Weiler, M., Eisele, G., Steinle, A., & Weller, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1627 · Cited by 305
Borg, C., Terme, M., Taïeb, J., Ménard, C., Flament, C., Robert, C., Maruyama, K., Wakasugi, H., Angevin, E., Thielemans, K., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21102 · Cited by 302
Natural killer cell-mediated immunosurveillance of human cancer
Malmberg, K.-J., Carlsten, M., Björklund, A., Sohlberg, E., Bryceson, Y. T., & Ljunggren, H.-G. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.08.002 · Cited by 299
Current Developments in Cancer Vaccines and Cellular Immunotherapy
Ribas, A., Butterfield, L. H., Glaspy, J. A., & Economou, J. S. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.041 · Cited by 295
The immune system in cancer metastasis: friend or foe?
Janssen, L. M. E., Ramsay, E. E., Logsdon, C. D., & Overwijk, W. W. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0283-9 · Cited by 292
Lundholm, M., Schröder, M., Nagaeva, O., Baranov, V., Widmark, A., Mincheva-Nilsson, L., & Wikström, P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108925 · Cited by 291
Andoniou, C. E., van Dommelen, S. L. H., Voigt, V., Andrews, D. M., Brizard, G., Asselin-Paturel, C., Delale, T., Stacey, K. J., Trinchieri, G., & Degli-Esposti, M. A. (2005) · Nature Immunology · doi:10.1038/ni1244 · Cited by 285
Sutherland, C. L., Chalupny, N. J., Schooley, K., VandenBos, T., Kubin, M., & Cosman, D. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.2.671 · Cited by 276
Lodoen, M., Ogasawara, K., Hamerman, J. A., Arase, H., Houchins, J. P., Mocarski, E. S., & Lanier, L. L. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021973 · Cited by 275
Self-citationCarayannopoulos, L. N., Naidenko, O. V., Fremont, D. H., & Yokoyama, W. M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.8.4079 · Cited by 274
Ghiringhelli, F., Ménard, C., Martin, F., & Zitvogel, L. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00445.x · Cited by 273
Borrego, F., Kabat, J., Kim, D.-K., Lieto, L., Maasho, K., Peña, J., Solana, R., & Coligan, J. E. (2002) · Molecular Immunology · doi:10.1016/s0161-5890(01)00107-9 · Cited by 271
KIR2DL4 (CD158d), an NK Cell-Activating Receptor with Inhibitory Potential
Faure, M., & Long, E. O. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.12.6208 · Cited by 268
Innate Immune Surveillance of Spontaneous B Cell Lymphomas by Natural Killer Cells and γδ T Cells
Street, S. E. A., Hayakawa, Y., Zhan, Y., Lew, A. M., MacGregor, D., Jamieson, A. M., Diefenbach, A., Yagita, H., Godfrey, D. I., & Smyth, M. J. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031981 · Cited by 264
Shaim, H., Shanley, M., Basar, R., Daher, M., Gumin, J., Zamler, D. B., Uprety, N., Wang, F., Huang, Y., Gabrusiewicz, K., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142116 · Cited by 263
Does the Immune System Naturally Protect Against Cancer?
Corthay, A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00197 · Cited by 261
Skov, S., Pedersen, M. T., Andresen, L., Thor Straten, P., Woetmann, A., & Ødum, N. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0599 · Cited by 259
Jinushi, M., Vanneman, M., Munshi, N. C., Tai, Y.-T., Prabhala, R. H., Ritz, J., Neuberg, D., Anderson, K. C., Carrasco, D. R., & Dranoff, G. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711293105 · Cited by 256
Ilander, M., Olsson-Strömberg, U., Schlums, H., Guilhot, J., Brück, O., Lähteenmäki, H., Kasanen, T., Koskenvesa, P., Söderlund, S., Höglund, M., et al. (2017) · Leukemia · doi:10.1038/leu.2016.360 · Cited by 250
Innate and adaptive immunity: specificities and signaling hierarchies revisited
Vivier, E., & Malissen, B. (2005) · Nature Immunology · doi:10.1038/ni1153 · Cited by 246
Stebbins, C. C., Watzl, C., Billadeau, D. D., Leibson, P. J., Burshtyn, D. N., & Long, E. O. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.17.6291-6299.2003 · Cited by 245
NKG2D ligands: key targets of the immune response
González, S., López-Soto, A., Suarez-Alvarez, B., López-Vázquez, A., & López-Larrea, C. (2008) · Trends in Immunology · doi:10.1016/j.it.2008.04.007 · Cited by 241
Systemic NKG2D Down-Regulation Impairs NK and CD8 T Cell Responses In Vivo
Wiemann, K., Mittrücker, H.-W., Feger, U., Welte, S. A., Yokoyama, W. M., Spies, T., Rammensee, H.-G., & Steinle, A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.2.720 · Cited by 240
Soluble MICA in malignant diseases
Holdenrieder, S., Stieber, P., Peterfi, A., Nagel, D., Steinle, A., & Salih, H. R. (2006) · International Journal of Cancer · doi:10.1002/ijc.21382 · Cited by 240
NKG2D and its ligands in cancer
Dhar, P., & Wu, J. D. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.02.004 · Cited by 239
The intersection of radiotherapy and immunotherapy: Mechanisms and clinical implications
Spiotto, M., Fu, Y.-X., & Weichselbaum, R. R. (2016) · Science Immunology · doi:10.1126/sciimmunol.aag1266 · Cited by 239
Hilpert, J., Grosse-Hovest, L., Grünebach, F., Buechele, C., Nuebling, T., Raum, T., Steinle, A., & Salih, H. R. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200796 · Cited by 238
Chen, S., Zhu, H., & Jounaidi, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02005-w · Cited by 234
DC-NK cell cross talk as a novel CD4+ T-cell–independent pathway for antitumor CTL induction
Adam, C., King, S., Allgeier, T., Braumüller, H., Lüking, C., Mysliwietz, J., Kriegeskorte, A., Busch, D. H., Röcken, M., & Mocikat, R. (2005) · Blood · doi:10.1182/blood-2004-09-3775 · Cited by 233
The innate immune response to tumors and its role in the induction of T‐cell immunity
Diefenbach, A., & Raulet, D. H. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18802.x · Cited by 228
Coudert, J. D., Zimmer, J., Tomasello, E., Cebecauer, M., Colonna, M., Vivier, E., & Held, W. (2005) · Blood · doi:10.1182/blood-2005-03-0918 · Cited by 226
MICA/NKG2D-mediated immunogene therapy of experimental gliomas.
Friese, M. A., Platten, M., Lutz, S. Z., Naumann, U., Aulwurm, S., Bischof, F., Bühring, H. ‐., DICHGANS, J., Rammensee, H., Steinle, A., et al. (2003) · PubMed · Cited by 224
A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development
Eckelhart, E., Warsch, W., Zebedin, E., Simma, O., Stoiber, D., Kolbe, T., Rülicke, T., Mueller, M., Casanova, E., & Sexl, V. (2011) · Blood · doi:10.1182/blood-2010-06-291633 · Cited by 222
Diermayr, S., Himmelreich, H., Durovic, B., Mathys-Schneeberger, A., Siegler, U., Langenkamp, U., Hofsteenge, J., Gratwohl, A., Tichelli, A., Paluszewska, M., et al. (2008) · Blood · doi:10.1182/blood-2007-07-101311 · Cited by 220
Natural Killer Cells in Human Cancer: From Biological Functions to Clinical Applications
Levy, E. M., Roberti, M. P., & Mordoh, J. (2011) · BioMed Research International · doi:10.1155/2011/676198 · Cited by 219
Killers 2.0: NK cell therapies at the forefront of cancer control
Hodgins, J. J., Khan, S. T., Park, M. M., Auer, R. C., & Ardolino, M. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129338 · Cited by 217
Immunobiology of Human NKG2D and Its Ligands
González, S., Groh, V., & Spies, T. (2006) · Current Topics in Microbiology and Immunology · doi:10.1007/3-540-27743-9_6 · Cited by 211
MCMV glycoprotein gp40 confers virus resistance to CD8+ T cells and NK cells in vivo
Krmpotić, A., Busch, D. H., Bubić, I., Gebhardt, F., Hengel, H., Hasan, M., Scalzo, A. A., Koszinowski, U. H., & Jonjić, S. (2002) · Nature Immunology · doi:10.1038/ni799 · Cited by 208
Boles, K. S., Barchet, W., Diacovo, T., Cella, M., & Colonna, M. (2005) · Blood · doi:10.1182/blood-2005-02-0817 · Cited by 208
Garrity, D., Call, M. E., Feng, J., & Wucherpfennig, K. W. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502439102 · Cited by 205
Tricking the balance: NK cells in anti-cancer immunity
Pahl, J., & Cerwenka, A. (2017) · Immunobiology · doi:10.1016/j.imbio.2015.07.012 · Cited by 205
Self-citationLymphocyte activation via NKG2D: towards a new paradigm in immune recognition?
Vivier, E., Tomasello, E., & Paul, P. (2002) · Current Opinion in Immunology · doi:10.1016/s0952-7915(02)00337-0 · Cited by 204
Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas
Kruschinski, A., Moosmann, A., Poschke, I., Norell, H., Chmielewski, M., Seliger, B., Kiessling, R., Blankenstein, T., Abken, H., & Charo, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804788105 · Cited by 197
McGilvray, R. W., Eagle, R. A., Watson, N. F. S., Al-Attar, A., Ball, G., Jafferji, I., Trowsdale, J., & Durrant, L. G. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0991 · Cited by 196
“In mouse models, it has been shown that tumor cell lines transfected with Rae1 are rejected in vivo via NKG2D-mediated immunity (18, 19).”
BackgroundPaschen, A., Sucker, A., Hill, B., Moll, I., Zapatka, M., Nguyen, X. D., Sim, G. C., Gutmann, I., Hassel, J., Becker, J. C., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0886 · Cited by 192
Metadata
- Authors
- Cerwenka, A., Baron, J. L., & Lanier, L. L.
- Affiliations
- University of California, San Francisco (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2001-09-18
- Volume
- 98
- Issue
- 20
- Pages
- 11521-11526
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC58762
- OpenAlex
- W2056645320
- Cited by
- 606
- References
- 34
- Citations by year
- 2026: 4 · 2025: 12 · 2024: 11 · 2023: 11 · 2022: 20 · 2021: 15 · 2020: 24 · 2019: 17 · 2018: 15 · 2017: 26 · 2016: 14 · 2015: 22 · 2014: 27 · 2013: 25 · 2012: 24
- FWCI
- 10.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- National Institutes of Health
- National Cancer Institute (CA89189, R01CA089189)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Keywords
- Rae1, NKG2D, natural killer cells, MHC class I, tumor rejection, missing self, NK cell receptors, immune surveillance, NK1.1+ T cells, tumor rechallenge
- MeSH terms
- Animals, B-Lymphocytes, Female, Immunoglobulin Fc Fragments, Immunologic Memory, Killer Cells, Natural, Lymphocyte Depletion, Lymphoma, Major Histocompatibility Complex, Membrane Proteins, Mice, Inbred C57BL, Recombinant Fusion Proteins, Transfection, Tumor Cells, Cultured, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.